Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Frequently asked questions
What sector does ANRO (ANRO) operate in?
ANRO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is ANRO (ANRO) current stock price?
As of the latest data, ANRO stock price is $22.11, with a previous close of $21.97. ANRO gained $0.14 in the last trading session, representing a 0.64% increase.
What is ANRO (ANRO) current market capitalization?
ANRO market cap is approximately 867.64 million.
What is ANRO (ANRO) Earnings Per Share (EPS)?
The trailing EPS is -$2.32, and the forward EPS is -$2.00.
What is ANRO (ANRO) EBITDA?
ANRO EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -27.15 million.
Does ANRO (ANRO) pay dividends?
No. ANRO does not pay a dividend.
What is ANRO (ANRO) beta (volatility) score?
ANRO has a beta of 1.156, meaning its volatility is roughly in line with the market.
